---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-016177"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:08:06.038366+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q1 net loss $4.0M, cash $1.7M; secures additional $3M debt from WFIA

## Summary
- Net loss $4.0M for Q1 2023, improved from $5.0M in Q1 2022; R&D expenses $2.1M (down 25% YoY).
- Cash and equivalents $1.7M at March 31, 2023; expects funding into Q3 2023 with new $3M debt.
- Received $3M additional debt from WFIA, increasing promissory note to $8M, unsecured at 15% interest, due Aug 2025.
- Completed transfer of PTR manufacturing to Societal CDMO; Phase 3 adult dose-optimization results expected Q3 2023.
- Entered joint commercialization agreement with Indegene for CTx-1301 upon FDA approval.

## SEC filing metadata
- accession: 0001493152-23-016177
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-016177
- JSON: https://secwatch.observer/filing/0001493152-23-016177.json
- Plain text: https://secwatch.observer/filing/0001493152-23-016177.txt

## Key facts
- Earnings Releases
  Cingulate Inc. reported financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: reported results
  source text: Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed ReleaseTM (PTRTM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm
- Material Agreements
  Cingulate Inc. amended Note with Werth Family Investment Associates LLC valued at from $5.0 million to $8.0 million (effective 2023-05-09).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Werth Family Investment Associates LLC
  - Value: from $5.0 million to $8.0 million
  - Effective: 2023-05-09
  source text: On May 9, 2023, CTx executed an amended and restated promissory note (the “Note”) in favor of WFIA that increased the principal amount of the Original Note from $5.0 million to $8.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.